Cite

HARVARD Citation

    Babagana, M. et al. (2020). The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies. Molecular carcinogenesis. 59 (1), pp. 5-14. [Online]. 
  
Back to record